Here's what Jim Cramer had to say about some of the stocks that callers offered up during the "Mad Money Lightning Round" Thursday evening:

Bristol-Myers Squibb (BMY) : "The made a new high today. You have to like it. I like Eli Lilly (LLY) too."

Mazor Robotics (MZOR) : "They're the next Intuitive Surgical (ISRG) . "

Himax Technologies (HIMX) : "I think this one is speculative."

Iridium Communications (IRDM) : "It's made a good comeback but I don't see any mojo to propel it higher."

ZAGG (ZAGG) : "I think there's a lot to this company."

McCormick (MKC) : "I like the acquisition."

Over on Real Money, Cramer explains what's happening in this market and what it means to your investment strategies. Get his insights with a free trial subscription to Real Money.

Cramer and the AAP team are focusing on the outlook for their charitable trust. Find out what they're telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

To read a full recap of this episode of "Mad Money," click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Action Alerts PLUS, which Cramer co-manages as a charitable trust, was long LLY.

More from Jim Cramer

Biotech's Coming Back to Life: Cramer's 'Off the Charts'

Biotech's Coming Back to Life: Cramer's 'Off the Charts'

Jim Cramer: Bank of America Expects 4% Economic Growth in Q2

Jim Cramer: Bank of America Expects 4% Economic Growth in Q2

Illinois Tool Works, Deutsche Bank, ForeScout: 'Mad Money' Lightning Round

Illinois Tool Works, Deutsche Bank, ForeScout: 'Mad Money' Lightning Round

Market Refuses To Go Lower: Cramer's 'Mad Money' Recap (Tuesday 7/17/18)

Market Refuses To Go Lower: Cramer's 'Mad Money' Recap (Tuesday 7/17/18)

Jim Cramer on Johnson & Johnson's Pharmaceuticals Sales Growth

Jim Cramer on Johnson & Johnson's Pharmaceuticals Sales Growth